Individuals Coming Off Weight-Loss Jabs Put On Pounds Four Times Faster Compared to Dieters
Fresh analysis indicates that patients who stop using new slimming jabs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who end traditional lifestyle programs.
Published data in a leading health publication demonstrates that while obese individuals often shed about a fifth of their body weight while using the jabs, the mass returns at an average rate of nearly a kilo each month after stopping.
"Individuals using such treatments must be aware of the risk of fast rebound weight gain when the therapy ends," cautioned expert Dr. Susan Jebb.
That rate of regain suggests a return to starting mass in about 18 months.
Analyzing Treatments
The analysis, which looked at dozens of studies involving over 9,000 of patients, compared the outcomes of these new drugs with other pills.
Scientists note that people who shed pounds through diet and exercise usually see a more gradual creep back—around 0.1 kg a month—once they finish.
Understanding the Rapid Regain
Doctors propose the mechanism of the jabs accounts for the heightened rebound.
These medications copy a natural hormone called GLP-1, which controls appetite.
"Artificially providing the hormone concentrations several times higher than the body's typical production may cause the system to produce less of its endogenous hormone, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication means hunger is no longer kept in check, making overeating much more probable."
A Chronic Condition?
Health authorities recommend the jabs for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals say that, given the likelihood of weight regain, the therapy is often long-term.
This opinion is echoed by drug manufacturers, who state that the results "underscore the long-term character of obesity," akin to managing conditions like diabetes.
Patient Accounts
Individuals who have discontinued the jabs report a intense resurgence of appetite.
"I experienced something activating and you become extremely hungry," said an individual.
This challenge is compounded if patients have not adopted lasting dietary or behavioural modifications during treatment.
Widespread Use
Recent estimates suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Use is greater among women compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
In conclusion, clinicians stress that while GLP-1 drugs are effective tools for weight loss, they are not a permanent solution and maintained weight loss relies on ongoing behavioural support.